The stock is in a volatile but pronounced recovery phase, having gained 44.78% over the past three months, yet it remains in a longer-term downtrend with a 1-year price change of -30.62%. As of the latest close of $117.95, the price is trading at approximately 63% of its 52-week range ($63.8 to $187.0), indicating it has recovered meaningfully from lows but remains well off its highs, suggesting a balance between renewed momentum and lingering skepticism. Recent short-term momentum is strongly positive, with the stock up 18.17% over the past month, significantly outperforming the SPY's 0.74% gain, which signals accelerating bullish sentiment diverging from the weak annual trend and potentially marking a trend reversal. Key technical support is anchored at the 52-week low of $63.8, while major resistance sits at the 52-week high of $187.0; a sustained breakout above this high would confirm a full bullish reversal, while a failure and breakdown below support would signal a resumption of the prior downtrend. The stock exhibits extreme volatility, evidenced by a 1-month relative strength of +17.43 against the market, which necessitates larger position sizing buffers for risk management.

Revenue growth is explosive but shows signs of sequential deceleration; Q4 2025 revenue reached $1.57 billion, representing a massive 110.3% year-over-year growth, yet this marks a slowdown from the 134% YoY growth seen in Q3 2025 ($1.36 billion), indicating growth remains hyper-strong but may be plateauing from an exceptionally high base. The company is deeply unprofitable on a net income basis, reporting a Q4 net loss of -$451.7 million, though it maintains a robust gross margin of 67.61%, which improved from 67.68% in the prior-year quarter; however, operating expenses are consuming gross profit, leading to an operating loss of -$89.6 million in Q4. The balance sheet and cash flow picture reveals significant financial risk and heavy investment; the debt-to-equity ratio is an extremely high 8.94, free cash flow over the trailing twelve months is a deeply negative -$7.25 billion, and the current ratio is a weak 0.46, indicating the company is funding its aggressive capex through substantial external debt and equity financing rather than internal cash generation.